A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results-Reference-Cited by-同舟云学术

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results

Published:2018-04 Issue: Volume:93 Page:19-27
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Pivot X.^ORCID,Bondarenko I.^ORCID,Nowecki Z.,Dvorkin M.,Trishkina E.,Ahn J.-H.,Im S.-A.^ORCID,Sarosiek T.^ORCID,Chatterjee S.,Wojtukiewicz M.Z.,Shparyk Y.,Moiseyenko V.,Bello M.,Semiglazov V.,Lee Y.,Lim J.

Funder

EudraCT

Samsung Bioepis Co., Ltd

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

2. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Engl J Med,2005

3. Adjuvant trastuzumab in HER2-positive breast cancer;Slamon;N Engl J Med,2011

4. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831;Perez;J Clin Oncol,2014

5. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccart-Gebhart;N Engl J Med,2005

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Define Critical Parameters of Trastuzumab-Mediated ADCC Assays via Assay Optimization Processes, Focusing on the Impact of Cryopreserved Effector Cells on Assay Performance;Cancers;2024-06-27

2. Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer;Current Oncology;2024-03-21

3. Biosimilar in Cervical Cancer;Biosimilars for Cancer Treatment;2024

4. Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study;Oncology;2023-10-27

5. Safety and efficacy comparisons of intravenous trastuzumab biosimilars to the reference product medicine in treatment‐naïve and switch‐over patients with breast cancer: a systematic and meta‐analysis;Journal of Pharmacy Practice and Research;2023-09-27